NL-OMON39171
Completed
Not Applicable
Phase I study of Everolimus combined with Metformin for patients with advanced cancer - Everolimus and Metformin for advanced cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- for which no standard treatment is available/ various types of cancer for which no standard treatment is available
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Signed informed content obtained prior to treatment
- •\- Cytological or histological confirmed malignancies
- •\- ECOG/ WHO performance 0\-2
- •\- Age \> 18 years
- •\- Life expectancy of at least 3 months
- •\- Adequate renal function (creatinine \< 150 µmol/L and/ or a creatinine clearance \> 60 ml/ L)
- •\- Adequate liver function (bilirubin \< 1\.5 times upper limit of normal, \* 3 × ULN for patients known to have Gilbert Syndrome, ALAT or ASAT \< 5\.0 times upper limit of normal in case of liver metastases and \< 2\.5 the upper limit of normal in absence of liver metastases).
- •\- Fasting serum cholesterol \* 7\.75 mmol/L and fasting triglycerides \* 2\.5 × ULN. In case one or both of these thresholds are exceeded, the patient can only be included after initiation of statin therapy or other lipid lowering drugs (eg fibrates), and when the above mentioned values have been achieved.
- •\- Adequate bone marrow function ((Absolute neutrophil count (ANC \* 1\.5 109/L ,platelets \> 100 x 10 9/L)
- •\- Mentally, physically, and geographically able to undergo treatment and follow up
Exclusion Criteria
- •\- Pregnancy (positive serum pregnancy test) and lactation
- •\- Serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator
- •\- Patients who have any severe and/or uncontrolled medical conditions such as:
- •unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction \* 6 months prior to randomization, serious uncontrolled cardiac arrhythmia, active or uncontrolled severe infection, cirrhosis, chronic active hepatitis or chronic persistent hepatitis (see screening for hepatitis Appendix A), severely impaired lung function
- •\- Uncontrolled diabetes as defined by fasting serum glucose \>2X ULN.
- •\- Patients with a known hypersensitivity to metformin
- •\- Use of metformin in the previous 6 months
- •\- Patients that have received everolimus in the past
- •\- Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin)
- •\-Concomitant use of strong CYP3A4, 3A5 and 2C8 inhibitors or inducers (see section 2\.1\.12
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study of preoperative everolimus in metastatic renal cell cancerISRCTN22979604Royal Marsden NHS Foundation Trust (UK)40
Active, not recruiting
Not Applicable
Everolimus and Fulvestrant therapy in postmenopausal metastatic Breast Cancer at patient treated with fulvestrant and who progressed on or after mTor inhibitor based treatmentpostmenopausal women with hormone receptor-positive, Her2 negative AI and fulvestrant treated, locally advanced or metastatic breast cancer, who progressed on prior fulvestrant and also received prior treatment with everolimus and exemestane. The treatment with fulvestrant is not required to be the last treatment administered as long as at some point in time a progression on fulvestrant has been ascertained.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000665-36-BEZ Brussel
Recruiting
Not Applicable
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
Active, not recruiting
Phase 1
Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocentric, prospective study.advanced/ or not resectable well differnciated pancreatic neuroendocrin tumorMedDRA version: 16.1Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-000888-41-ITFondazione IRCCS Istituto Nazionale dei tumori43
Completed
Phase 2
Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.Kidney cancer10038364NL-OMON43872Vrije Universiteit Medisch Centrum96